Nicotinamide riboside
- Generic Name
- Nicotinamide riboside
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H15N2O5
- CAS Number
- 1341-23-7
- Unique Ingredient Identifier
- 0I8H2M0L7N
- Background
Nicotinamide riboside is under investigation in clinical trial NCT03432871 (Nicotinamide Riboside and Mitochondrial Biogenesis).
- Associated Conditions
- -
- Associated Therapies
- -
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT06567717
- Locations
- 🇺🇸
Cedars-Sinai, Los Angeles, California, United States
NAD Supplementation and Vascular Health in PAD
- Conditions
- Interventions
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 8
- Registration Number
- NCT06534944
- Locations
- 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside
- Conditions
- Interventions
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- The University of Queensland
- Target Recruit Count
- 10
- Registration Number
- NCT06324877
- Locations
- 🇦🇺
Queensland Children's Hospital, Brisbane, Queensland, Australia
The Effect of NAD Supplementation on Brain Vascular Health in Aging
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 214
- Registration Number
- NCT05483465
- Locations
- 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection
- Conditions
- Interventions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2023-12-26
- Target Recruit Count
- 28
- Registration Number
- NCT04818216
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸University Health Systems, San Antonio, Texas, United States
🇺🇸The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 40
- Registration Number
- NCT04528004
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia
- Conditions
- Interventions
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04430517
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Donna Hammond, PhD
- Target Recruit Count
- 48
- Registration Number
- NCT04112641
- Locations
- 🇺🇸
Donna Hammond, Iowa City, Iowa, United States
Nicotinamide Riboside in Hospitalized Patients
- Conditions
- Interventions
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 57
- Registration Number
- NCT04110028
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- Conditions
- Interventions
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 118
- Registration Number
- NCT04040959
- Locations
- 🇺🇸
UColorado, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.